Aaron Cumpston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aaron Cumpston has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Michael Craig
Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV
8 shared publicationsLauren Veltri
Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University Cancer Institute, Morgantown, WV, USA; Department of Medical Oncology, West Virginia University Medicine. Morgantown, WV, USA
7 shared publications- Sijin Wen
West Virginia University Cancer Institute, West Virginia University, Morgantown, WV 26506, USA
7 shared publications Abraham S. Kanate
Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV
6 shared publications- Alexandra Shillingburg
Levine Cancer Institute, Charlotte, NC, USA
5 shared publications - Lauren Veltri
West Virginia University, Morgantown, WV
4 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1426.e1-1426.e10
Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma
- 5 August 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1426.e1-1426.e10
Open AccessImpact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma
- 19 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1415.e1-1415.e5
Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study
- 19 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1415.e1-1415.e5
Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study
- 3 March 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (3) , e70005
Evaluation of Titer‐Proven Response Rates of Pediatric Hepatitis B‐Combination Vaccines in Adult Hematopoietic Cell Transplant Recipients
Background: Patients who have undergone hematopoietic cell transplant (HCT) should be revaccinated with common childhood vaccines due to loss of immunity. It is common for transplant centers to encourage adherence by administering combination vaccines to alleviate high vaccine burden. A combination product containing pediatric doses of hepatitis B surface antigen (10 µg) is commonly utilized, although limited data are available on response post‐HCT.Methods: The primary objective of this study was to determine the efficacy of a low‐dose, combination hepatitis B vaccine by assessing titer‐proven response rates. The secondary objective was to characterize factors that influence non‐response. Post‐HCT patients were included in this analysis if they received all three post‐HCT doses of low‐dose DTaP‐HepB‐IPV with a subsequently documented hepatitis B titer result. Following the successful completion of the protocol, patients were considered responders to the vaccine if they had measurable titers ≥10 mIU/mL.Results: Thirty‐nine patients met inclusion criteria. A serologic response to the vaccine series was observed in 21 of the 39 patients (54%). Allogeneic HCT recipients were found to have a response rate of 76%, whereas autologous recipients were less likely to respond (response rate 36%, p = 0.02).Conclusion: An appropriate response to a low‐dose, combination hepatitis B vaccine was observed in allogeneic HCT recipients. Autologous response rates are low, though this finding is consistent with prior literature.
- 3 March 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (3) , e70005
Evaluation of Titer‐Proven Response Rates of Pediatric Hepatitis B‐Combination Vaccines in Adult Hematopoietic Cell Transplant Recipients
Background: Patients who have undergone hematopoietic cell transplant (HCT) should be revaccinated with common childhood vaccines due to loss of immunity. It is common for transplant centers to encourage adherence by administering combination vaccines to alleviate high vaccine burden. A combination product containing pediatric doses of hepatitis B surface antigen (10 µg) is commonly utilized, although limited data are available on response post‐HCT.Methods: The primary objective of this study was to determine the efficacy of a low‐dose, combination hepatitis B vaccine by assessing titer‐proven response rates. The secondary objective was to characterize factors that influence non‐response. Post‐HCT patients were included in this analysis if they received all three post‐HCT doses of low‐dose DTaP‐HepB‐IPV with a subsequently documented hepatitis B titer result. Following the successful completion of the protocol, patients were considered responders to the vaccine if they had measurable titers ≥10 mIU/mL.Results: Thirty‐nine patients met inclusion criteria. A serologic response to the vaccine series was observed in 21 of the 39 patients (54%). Allogeneic HCT recipients were found to have a response rate of 76%, whereas autologous recipients were less likely to respond (response rate 36%, p = 0.02).Conclusion: An appropriate response to a low‐dose, combination hepatitis B vaccine was observed in allogeneic HCT recipients. Autologous response rates are low, though this finding is consistent with prior literature.
- Open Access
- 9 April 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (7) , 371.e1-371.e4
Evaluation of the Pharmacokinetic Interaction Between Letermovir and Tacrolimus in Allogeneic Hematopoietic Cell Transplantation Recipients
- 9 April 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (7) , 371.e1-371.e4
Open AccessEvaluation of the Pharmacokinetic Interaction Between Letermovir and Tacrolimus in Allogeneic Hematopoietic Cell Transplantation Recipients
- 24 June 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13676
Impact of anti‐anaerobic antibiotic activity on graft‐versus‐host disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients at an institution that utilizes antibiotic cycling
Background: At our institution, antibiotic cycling for febrile neutropenia is utilized to increase heterogeneity of antibiotic exposure in patients who have undergone an allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Development of acute graft‐versus‐host disease (aGVHD) has been associated with low diversity within stool microbiota. To date, discordant outcomes have been reported implicating anti‐anaerobic antibiotic use with the development of aGVHD, and there is currently a lack of published data available in an antibiotic cycled environment. The objective of this study was to determine if there is a difference in the rate of aGVHD in patients who receive anti‐anaerobic cycled antibiotics compared with other cycled antibiotics.Methods: This was a retrospective, observational study evaluating rates of aGVHD in patients who received antibiotics with anaerobic vs non‐anaerobic coverage post‐allo‐HSCT from January 2008 to January 2018. Univariate and multivariable analyses were performed to assess associations with aGVHD. Secondary outcomes include rate of all stages of aGVHD, progression‐free survival, overall survival, 100‐day treatment‐related mortality (TRM), and 1‐year TRM.Results: A total of 273 patients were included in the study. Baseline characteristics were similar between groups, except patients who received anti‐anaerobic antibiotics had more unrelated donors (P = .002), were more likely to get myeloablative preparatory regimens (P = .009), had less subtherapeutic calcineurin inhibitor serum concentrations (P = .001), and more often received T‐cell depletion (P = .004). The incidence of grades II–IV aGVHD post‐HSCT in patients who received anti‐anaerobic antibiotics was 32.6% compared with 18.8% in patients who received other antibiotics (P = .015). Multivariable analysis showed that the occurrence of grades II–IV aGVHD was associated with cytomegalovirus reactivation (OR = 2.1, 95% CI = 1.0–4.5, P = .047), unrelated donors (OR = 6.1, 95% CI = 2.3–16.6, P < .001), and use of anti‐anaerobic antibiotics (OR = 2.3, 95% CI = 1.1–4.8, P = .021). A 100‐day TRM in patients who received anti‐anaerobic antibiotics was 9.6% compared with 3.6% in patients who received other antibiotics (P = .046). One‐year TRM in patients who received anti‐anaerobic antibiotics was 25.2% compared with 13.8% in patients who received other antibiotics (P = .017). There was no statistically significant difference seen between groups in progression free survival or overall survival.Conclusion: Variability in baseline characteristics limits ability to make strong conclusions, but patients who received antibiotics with anaerobic coverage during the first 30 days after an allogeneic HSCT appeared to be at an increased risk of developing aGVHD and TRM. Larger well‐controlled trials are warranted to further clarify these relationships.
- 24 June 2021
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4) , e13676
Impact of anti‐anaerobic antibiotic activity on graft‐versus‐host disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients at an institution that utilizes antibiotic cycling
Background: At our institution, antibiotic cycling for febrile neutropenia is utilized to increase heterogeneity of antibiotic exposure in patients who have undergone an allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Development of acute graft‐versus‐host disease (aGVHD) has been associated with low diversity within stool microbiota. To date, discordant outcomes have been reported implicating anti‐anaerobic antibiotic use with the development of aGVHD, and there is currently a lack of published data available in an antibiotic cycled environment. The objective of this study was to determine if there is a difference in the rate of aGVHD in patients who receive anti‐anaerobic cycled antibiotics compared with other cycled antibiotics.Methods: This was a retrospective, observational study evaluating rates of aGVHD in patients who received antibiotics with anaerobic vs non‐anaerobic coverage post‐allo‐HSCT from January 2008 to January 2018. Univariate and multivariable analyses were performed to assess associations with aGVHD. Secondary outcomes include rate of all stages of aGVHD, progression‐free survival, overall survival, 100‐day treatment‐related mortality (TRM), and 1‐year TRM.Results: A total of 273 patients were included in the study. Baseline characteristics were similar between groups, except patients who received anti‐anaerobic antibiotics had more unrelated donors (P = .002), were more likely to get myeloablative preparatory regimens (P = .009), had less subtherapeutic calcineurin inhibitor serum concentrations (P = .001), and more often received T‐cell depletion (P = .004). The incidence of grades II–IV aGVHD post‐HSCT in patients who received anti‐anaerobic antibiotics was 32.6% compared with 18.8% in patients who received other antibiotics (P = .015). Multivariable analysis showed that the occurrence of grades II–IV aGVHD was associated with cytomegalovirus reactivation (OR = 2.1, 95% CI = 1.0–4.5, P = .047), unrelated donors (OR = 6.1, 95% CI = 2.3–16.6, P < .001), and use of anti‐anaerobic antibiotics (OR = 2.3, 95% CI = 1.1–4.8, P = .021). A 100‐day TRM in patients who received anti‐anaerobic antibiotics was 9.6% compared with 3.6% in patients who received other antibiotics (P = .046). One‐year TRM in patients who received anti‐anaerobic antibiotics was 25.2% compared with 13.8% in patients who received other antibiotics (P = .017). There was no statistically significant difference seen between groups in progression free survival or overall survival.Conclusion: Variability in baseline characteristics limits ability to make strong conclusions, but patients who received antibiotics with anaerobic coverage during the first 30 days after an allogeneic HSCT appeared to be at an increased risk of developing aGVHD and TRM. Larger well‐controlled trials are warranted to further clarify these relationships.
- 16 August 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 22 (6) , e13438
Prospective assessment of Clostridioides (formerly Clostridium) difficile colonization and acquisition in hematopoietic stem cell transplant patients
Background: Patients undergoing hematopoietic stem cell transplant (HSCT) possess numerous risk factors for Clostridioides (formerly Clostridium) difficile infection (CDI) and experience a high rate of diarrhea. Colonization rates of Clostridium difficile vary greatly among subgroup analyses with recent studies demonstrating colonization rates in the blood and marrow transplant units up to nine times that of the general population.Methods: The primary objectives of this study were to identify the rate of C difficile colonization and acquisition in HSCT patients admitted to the blood and marrow transplant unit. This was a prospective study that included all adult patients admitted for hematopoietic stem cell transplantation. Stool specimens were routinely collected on admission and weekly thereafter for a maximum of six samples per patient.Results: Forty‐two patients met inclusion criteria and had baseline samples available for analysis. The rate of C difficile colonization on admission was 24%, and an additional 9% of patients acquired the organism during admission. Twelve percent of patients developed CDI that was diagnosed clinically. Univariate analysis showed an increased risk of colonization for patients with three or more prior chemotherapy cycles.Conclusions: Given high colonization rates coupled with high risk of CDI in this population, providers must be judicious when testing for CDI and interpreting test results for HSCT patients.
- 16 August 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 22 (6) , e13438
Prospective assessment of Clostridioides (formerly Clostridium) difficile colonization and acquisition in hematopoietic stem cell transplant patients
Background: Patients undergoing hematopoietic stem cell transplant (HSCT) possess numerous risk factors for Clostridioides (formerly Clostridium) difficile infection (CDI) and experience a high rate of diarrhea. Colonization rates of Clostridium difficile vary greatly among subgroup analyses with recent studies demonstrating colonization rates in the blood and marrow transplant units up to nine times that of the general population.Methods: The primary objectives of this study were to identify the rate of C difficile colonization and acquisition in HSCT patients admitted to the blood and marrow transplant unit. This was a prospective study that included all adult patients admitted for hematopoietic stem cell transplantation. Stool specimens were routinely collected on admission and weekly thereafter for a maximum of six samples per patient.Results: Forty‐two patients met inclusion criteria and had baseline samples available for analysis. The rate of C difficile colonization on admission was 24%, and an additional 9% of patients acquired the organism during admission. Twelve percent of patients developed CDI that was diagnosed clinically. Univariate analysis showed an increased risk of colonization for patients with three or more prior chemotherapy cycles.Conclusions: Given high colonization rates coupled with high risk of CDI in this population, providers must be judicious when testing for CDI and interpreting test results for HSCT patients.
- Open Access
- 11 June 2017
- Published by Wiley in Leukemia Research and Treatment
- Vol. 2017, 1-6
Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
Posaconazole (PCZ) is frequently used for prophylaxis against invasive fungal infections (IFI) in patients undergoing induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Posaconazole is commercially available as an oral suspension (PCZ-susp) and as a delayed-release tablet (PCZ-tab). Differences in absorption and bioavailability between these formulations may result in variability in serum posaconazole concentrations. The primary objective of this retrospective analysis was to compare attainment of goal serum posaconazole steady state concentrations () ≥ 700 ng/ml in patients with AML/MDS undergoing induction chemotherapy receiving PCZ-susp 600–800 mg per day versus PCZ-Tablet 300 mg twice daily for one day, followed by 300 mg daily . Sixty-two patients (97%) in the PCZ-tab group compared to 20 patients (17%) in the PCZ-susp group achieved goal . Median posaconazole serum was 1,665 ng/ml (522–3,830 mg/ml) in the PCZ-tab group versus 390 ng/ml (51–1,870 ng/ml) in the PCZ-susp group . There was no difference in hepatotoxicity, QTc prolongation, or breakthrough IFI. Patients receiving PCZ-tab were significantly more likely to achieve goal and demonstrated higher versus patients receiving PCZ-susp. Prospective studies are needed to assess the potential correlation of serum concentrations with efficacy and toxicity.- 11 June 2017
- Published by Wiley in Leukemia Research and Treatment
- Vol. 2017, 1-6
Open AccessEvaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
Posaconazole (PCZ) is frequently used for prophylaxis against invasive fungal infections (IFI) in patients undergoing induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Posaconazole is commercially available as an oral suspension (PCZ-susp) and as a delayed-release tablet (PCZ-tab). Differences in absorption and bioavailability between these formulations may result in variability in serum posaconazole concentrations. The primary objective of this retrospective analysis was to compare attainment of goal serum posaconazole steady state concentrations () ≥ 700 ng/ml in patients with AML/MDS undergoing induction chemotherapy receiving PCZ-susp 600–800 mg per day versus PCZ-Tablet 300 mg twice daily for one day, followed by 300 mg daily . Sixty-two patients (97%) in the PCZ-tab group compared to 20 patients (17%) in the PCZ-susp group achieved goal . Median posaconazole serum was 1,665 ng/ml (522–3,830 mg/ml) in the PCZ-tab group versus 390 ng/ml (51–1,870 ng/ml) in the PCZ-susp group . There was no difference in hepatotoxicity, QTc prolongation, or breakthrough IFI. Patients receiving PCZ-tab were significantly more likely to achieve goal and demonstrated higher versus patients receiving PCZ-susp. Prospective studies are needed to assess the potential correlation of serum concentrations with efficacy and toxicity. - Open Access
- 14 May 2017
- Published by Wiley in Advances in Hematology
- Vol. 2017, 1-4
Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/refractory acute myeloid leukemia (RR-AML) is associated with poor prognosis and long-term disease-free survival requires allogeneic hematopoietic cell transplantation (allo-HCT). Limited data exists, regarding the optimal regimen to obtain remission prior to allo-HCT. Single agent high-dose cytarabine (10–12 doses administered every 12 hours) has been previously used as induction therapy. Six-dose high-dose cytarabine (HiDAC-6), commonly used as a consolidation regimen, has never been evaluated as induction therapy. We present a retrospective review of 26 consecutive patients with RR-AML receiving single agent cytarabine 3 g/m2intravenously every 12 hours on days 1, 3, and 5 for a total of six doses (HiDAC-6). Median follow-up for surviving patients was 10.4 months (range 1.6–112.2 months). Complete remission was obtained in 62% (54% CR and 8% CRi) of the patients. The median relapse-free survival (RFS) was 22.3 months (range 0.7–112 months), event-free survival (EFS) was 4.7 months (range 0.5–112 months), and the overall survival (OS) was 9.6 months (range 1–112 months). Thirty-five percent of patients were able to subsequently proceed to allo-HCT. Treatment-related toxicities included neutropenic fever (38%), infection (35%), neurotoxicity (8%), and skin toxicity (8%). This is the first study to demonstrate HiDAC-6 as an active treatment option for younger patients with RR-AML which can effectively serve as a bridge to allo-HCT without significant toxicity.
- 14 May 2017
- Published by Wiley in Advances in Hematology
- Vol. 2017, 1-4
Open AccessOutcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/refractory acute myeloid leukemia (RR-AML) is associated with poor prognosis and long-term disease-free survival requires allogeneic hematopoietic cell transplantation (allo-HCT). Limited data exists, regarding the optimal regimen to obtain remission prior to allo-HCT. Single agent high-dose cytarabine (10–12 doses administered every 12 hours) has been previously used as induction therapy. Six-dose high-dose cytarabine (HiDAC-6), commonly used as a consolidation regimen, has never been evaluated as induction therapy. We present a retrospective review of 26 consecutive patients with RR-AML receiving single agent cytarabine 3 g/m2intravenously every 12 hours on days 1, 3, and 5 for a total of six doses (HiDAC-6). Median follow-up for surviving patients was 10.4 months (range 1.6–112.2 months). Complete remission was obtained in 62% (54% CR and 8% CRi) of the patients. The median relapse-free survival (RFS) was 22.3 months (range 0.7–112 months), event-free survival (EFS) was 4.7 months (range 0.5–112 months), and the overall survival (OS) was 9.6 months (range 1–112 months). Thirty-five percent of patients were able to subsequently proceed to allo-HCT. Treatment-related toxicities included neutropenic fever (38%), infection (35%), neurotoxicity (8%), and skin toxicity (8%). This is the first study to demonstrate HiDAC-6 as an active treatment option for younger patients with RR-AML which can effectively serve as a bridge to allo-HCT without significant toxicity.
- Open Access
- 28 November 2016
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 52 (2) , 321-322
Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL)
- 28 November 2016
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 52 (2) , 321-322
Open AccessLong-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL)